Experimed

GÖNDERBİLGİ
EnglishTürkçe

Araştırma Makalesi


DOI :10.26650/experimed.1527119   IUP :10.26650/experimed.1527119    Tam Metin (PDF)

Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly

Omar Yasir Shakir, Safaa Ehssan Atta, Karam Gharab, Lujain A. Ghannawi, Abbas M. Rahmah

Objective: Asprosin (ASP) is a modern adipokine produced from white adipose tissue that is linked to metabolic disorders such as obesity and diabetes. Acromegalic syndrome results from excessive pituitary growth hormone (GH) secretion, leading to increased insulin-like growth factor-1 (IGF-1) production, usually due to a pituitary adenoma. The serum ASP levels were higher in acromegaly patients (AC-PTs) than in healthy controls. The aim of the study was to explore ASP levels in AC-PTs compared with healthy controls, considering gender, diabetes status, treatment duration, and hypertension.

Materials and Methods: Fifty AC-PTs with different body mass index, sex, age, diabetes, and blood pressure were enrolled in this study. IGF-1, GH, and fasting blood glucose (FBG) levels were measured alongside 30 healthy controls. In addition, enzyme-linked immunoassay (ELISA) was used to measure ASP.

Results: There was no significant difference in ASP levels between AC-PTs and healthy controls (p>0.05). Moreover, the current study showed no statistically significant difference in ASP levels among the subgroups categorized according to the patient’s gender, diabetes status, hypertension, and treatment course.

Conclusion: ASP levels revealed no difference between Iraqi AC-PTs and control group; ASP is not affected by hormonal changes that are typically associated with acromegaly.

Anahtar Kelimeler: Acromegaly, Adipokine, Asprosin, GH, IGF-1, Pituitary Adenoma

PDF Görünüm

Referanslar

  • 1. Vilar L, Vilar ÇF, LYra R, LYra R, Naves LA. AcromegalY: clinical features at diagnosis. PituitarY 2017; 20: 22-32. google scholar
  • 2. Çolao A, Pivonello Ç, Grasso LFS, Pirchio R. AcromegalY. ln: La Rosa, S., Uccella, S. (eds) Endocrine PathologY. EncYclopedia of PathologY. Çham: Springer; 2022. p. 9-11. google scholar
  • 3. Ershadinia N, Tritos NA. Diagnosis and treatment of acromegalY: an update. MaYo Çlin Proc 2022; 97(2): 333-46. google scholar
  • 4. Saadi MT, Mohammed NUG, Abed BA, Farhan LO, Salman lN. ValiditY of galactin-3 in acromegalY: comparison with traditional markers. lr J Med Sci 2024; 193(4): 1837-41. google scholar
  • 5. Farhan LO, Abed BA, Salman lN. lnsulin like growth factor binding protein 7 as a novel diagnostic marker in sera of lraqi patients with acromegalY. Baghdad Sci J 2023; 20(3 Suppl): 0979. google scholar
  • 6. Çhanson P, Salenave S. AcromegalY. Orphanet J Rare Dis 2008; 3: 1-17. google scholar
  • 7. Ghannawi L, Gharab K, Hadi M, Shakir O, Rahmah A. Spexin level in growth hormone deficiencY lraqi children. Ukr Biochem J 2024; 96(4): 55-61. google scholar
  • 8. Turki TG. The Association of growth hormone releasing hormone gene polYmorphism with acromegalY in patients from lraq. AL-Qasim Green UniversitY, Master thesis. 2023. google scholar
  • 9. Sharma R, Kopchick JJ, Puri V, Sharma VM. Effect of growth hormone on insulin signaling. Mol Çell Endocrinol 2020; 518: 111038. google scholar
  • 10. Olarescu NÇ, Bollerslev J. The impact of adipose tissue on insulin resistance in acromegalY. Trends Endocrinol Metab 2016; 27(4): 226-37. google scholar
  • 11. Kuker AP, Shen W, Jin Z, Çhen J, Bruce JN, Freda PU. Long-term outcome of bodY composition, ectopic lipid, and insulin resistance changes with surgical treatment of acromegalY. J Endocr Soc 2023; 7(5): bvad028. google scholar
  • 12. Abreu A, Român-Gonzâlez A, Tovar H, Maestre K, Builes-Barrera CA, Nessim E, et al. Characterizing the burden of uncontrolled acromegalY-a description of real-world patient characteristics in Colombia. Rev Colomb Endocrinol Diabetes Metab 2022; 9(2): e678. google scholar
  • 13. Bona C, Prencipe N, Berton A, Bioletto F, Parasiliti-Caprino M, Gasco V, et al. Mean GH profile is more accurate than single fasting GH in the evaluation of acromegalY disease control during somatostatin receptor ligands therapY. J Endocrinol lnvest 2022; 45(10): 1955-65. google scholar
  • 14. Peixe C, Sânchez-Garcîa M, Grossman AB, Korbonits M, Marques P. Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or lGF-1 levels do not alwaYs diagnose acromegalY. Growth Horm lGF Res 2022; 64: 101467. google scholar
  • 15. Gozel N, Kilinc F. lnvestigation of plasma asprosin and saliva levels in newlY diagnosed tYpe 2 diabetes mellitus patients treated with metformin. EndokrYnol Pol 2021; 72(1): 37-43. google scholar
  • 16. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell 2016; 165(3): 566-79. google scholar
  • 17. BaYkus Y, Yavuzkir S, UstebaY S, Ugur K, Deniz R, AYdin S. Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus. Peptides 2019; 120: 170132. google scholar
  • 18. Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan l, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polYcYstic ovarY sYndrome. GYnecol Endocrinol 2019; 35(3): 220-3. google scholar
  • 19. Atta SE, Abed BA, Salman lN, Ghannawi LA. Review of Asprosin as new biomarker for diagnosis of different diseases. Univ Thi-Qar J Sci 2023; 10(2): 160-4. google scholar
  • 20. Janoschek R, Hoffmann T, Morcos YAT, Sengle G, Dötsch J, Hucklenbruch-Rother E. Asprosin in pregnancY and childhood. Mol Cell Pediatr 2020; 7: 1-5. google scholar
  • 21. Farhan LO, Salman lN. A review on the role of novel adipokine lsthmin-1 and Subfatin in human tYpe 2 diabetes mellitus. Univ Thi-Qar J Sci 2023; 10(2): 181-6. google scholar
  • 22. Lefta NA, Abed AY, Abed BA. Estimation of Asprosin levels in female lraqi patients with tYpe 2 diabetes and hYpothYroidism. J Med Chem Sci 2023; 6(2): 433-9. google scholar
  • 23. Liu Y, Long A, Chen L, Jia L, Wang Y. The Asprosin-OLFR734 modüle regulates appetitive behaviors. Cell Discov 2020; 6(1): 19. google scholar
  • 24. Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: a novel plaYer in metabolic diseases. Front Endocrinol 2020; 11: 64. google scholar
  • 25. Wang CY, Lin TA, Liu KH, Liao CH, Liu YY, Wu VC, et al. Serum asprosin levels and bariatric surgerY outcomes in obese adults. lnt J Obes (Lond) 2019; 43(5): 1019-25. google scholar
  • 26. Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y, et al. OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell Metab 2019; 30(2): 319-28.e8. google scholar
  • 27. Nijenhuis-Noort EC, Berk KA, Neggers SJ, van der LelY AJ. The fascinating interplaY between growth hormone, insulin-like growth factor-1, and insulin. Endocrinol Metab 2024; 39(1): 83. google scholar
  • 28. Wiecek M, SzYmura J, KusmierczYk J, Lipowska M, SzYgula Z. Whole-bodY crYotherapY improves asprosin secretion and insulin sensitivitY in postmenopausal women-perspectives in the Management of tYpe 2 diabetes. Biomolecules 2023; 13(11): 1602. google scholar
  • 29. Muthu ML, Reinhardt DP. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. J Cell Commun Signal 2020; 14(2): 159-73. google scholar
  • 30. Kim JH, Chae HW, Chin SO, Ku CR, Park KH, Lim DJ, et al. Diagnosis and treatment of growth hormone deficiencY: a position statement from the Korean Endocrine SocietY and Korean SocietY of Pediatric EndocrinologY. Endocrinol Metab 2020; 35(2): 272. google scholar
  • 31. Hekim MG, Kelestemur MM, Bulmus FG, Bilgin B, Bulut F, Gokdere E, et al. Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Arch PhYsiol Biochem 2023; 129(5): 1038-44. google scholar
  • 32. Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in tYpe 2 diabetes mellitus and independentlY associated with fasting glucose and triglYceride. Clin Chim Acta 2019; 489: 183-8. google scholar
  • 33. Wang M, Yin C, Wang L, Liu Y, Li H, Li M, et al. Serum asprosin concentrations are increased and associated with insulin resistance in children with obesitY. Ann Nutr Metab 2020; 75(4): 205-12. google scholar
  • 34. Sunnetci Silistre E, Hatipogl HU. lncreased serum circulating asprosin levels in children with obesitY. Pediatr lnt 2020; 62(4): 467-76. google scholar
  • 35. Moradi N, Fouani FZ, Vatannejad A, Bakhti Arani A, Shahrzad S, Fadaei R. Serum levels of asprosin in patients diagnosed with coronarY arterY disease (CAD): a case-control studY. Lipids Health Dis 2021; 20(1): 88. google scholar
  • 36. Ke X, Duan L, Gong F, Zhang Y, Deng K, Yao Y, et al. Serum levels of asprosin, a novel adipokine, are significantlY lowered in patients with acromegalY. lnt J Endocrinol 2020: 8855996. google scholar
  • 37. Kumar U, Singh S. Role of somatostatin in the regulation of central and peripheral factors of satiety and obesity. Int J Mol Sci 2020; 21(7): 2568. google scholar
  • 38. Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes 2020; 69(4): 559-66. google scholar
  • 39. Wojciak G, Szymura J, Szygula Z, Gradek J, Wiecek M. The effect of repeated whole-body cryotherapy on SIRT1 and SIRT3 concentrations and oxidative status in older and young men performing different levels of physical activity. Antioxidants 2020; 10(1): 37. google scholar
  • 40. Liu L, Liu Y, Huang M, Zhang M, Zhu C, Chen X, et al. The effects of asprosin on exercise-intervention in metabolic diseases. Front Physiol 2022; 13: 907358. google scholar
  • 41. Challa TD. Regulation of adipogenesis and energy metabolism through the cross-talk between adipose tissue, gastrointestinal wall and the brain: Evidence from adipokines and incretin hormones. ETH Zurich, Doctoral thesis; 2014. google scholar
  • 42. Dal J, Skov BG, Andersen M, Feldt-Rasmussen U, Feltoft CL, Karmisholt J, et al. Sex differences in acromegaly at diagnosis: a nationwide cohort study and meta-analysis of the literature. Clin Endocrinol 2021; 94(4): 625-35. google scholar
  • 43. Wang W, Duan X, Huang Z, Pan Q, Chen C, Guo L. The GH-IGF-1 axis in circadian rhythm. Front Mol Neurosci 2021; 14: 742294. google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Yasir Shakir, O., Atta, S.E., Gharab, K., Ghannawi, L.A., & Rahmah, A.M. (2025). Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly. Experimed, 15(1), 49-56. https://doi.org/10.26650/experimed.1527119


AMA

Yasir Shakir O, Atta S E, Gharab K, Ghannawi L A, Rahmah A M. Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly. Experimed. 2025;15(1):49-56. https://doi.org/10.26650/experimed.1527119


ABNT

Yasir Shakir, O.; Atta, S.E.; Gharab, K.; Ghannawi, L.A.; Rahmah, A.M. Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly. Experimed, [Publisher Location], v. 15, n. 1, p. 49-56, 2025.


Chicago: Author-Date Style

Yasir Shakir, Omar, and Safaa Ehssan Atta and Karam Gharab and Lujain A. Ghannawi and Abbas M. Rahmah. 2025. “Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly.” Experimed 15, no. 1: 49-56. https://doi.org/10.26650/experimed.1527119


Chicago: Humanities Style

Yasir Shakir, Omar, and Safaa Ehssan Atta and Karam Gharab and Lujain A. Ghannawi and Abbas M. Rahmah. “Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly.” Experimed 15, no. 1 (May. 2025): 49-56. https://doi.org/10.26650/experimed.1527119


Harvard: Australian Style

Yasir Shakir, O & Atta, SE & Gharab, K & Ghannawi, LA & Rahmah, AM 2025, 'Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly', Experimed, vol. 15, no. 1, pp. 49-56, viewed 22 May. 2025, https://doi.org/10.26650/experimed.1527119


Harvard: Author-Date Style

Yasir Shakir, O. and Atta, S.E. and Gharab, K. and Ghannawi, L.A. and Rahmah, A.M. (2025) ‘Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly’, Experimed, 15(1), pp. 49-56. https://doi.org/10.26650/experimed.1527119 (22 May. 2025).


MLA

Yasir Shakir, Omar, and Safaa Ehssan Atta and Karam Gharab and Lujain A. Ghannawi and Abbas M. Rahmah. “Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly.” Experimed, vol. 15, no. 1, 2025, pp. 49-56. [Database Container], https://doi.org/10.26650/experimed.1527119


Vancouver

Yasir Shakir O, Atta SE, Gharab K, Ghannawi LA, Rahmah AM. Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly. Experimed [Internet]. 22 May. 2025 [cited 22 May. 2025];15(1):49-56. Available from: https://doi.org/10.26650/experimed.1527119 doi: 10.26650/experimed.1527119


ISNAD

Yasir Shakir, Omar - Atta, SafaaEhssan - Gharab, Karam - Ghannawi, LujainA. - Rahmah, AbbasM.. “Assessing Serum Asprosin Levels among Iraqi Individuals Diagnosed with Acromegaly”. Experimed 15/1 (May. 2025): 49-56. https://doi.org/10.26650/experimed.1527119



ZAMAN ÇİZELGESİ


Gönderim02.08.2024
Kabul23.01.2025
Çevrimiçi Yayınlanma10.03.2025

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ



İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.